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Drug-induced immune thrombocytopenia: 




Drug-induced immune thrombocytopenia (DIIT) is a relatively 
uncommon adverse reaction caused by drug-dependent antibodies 
(DDAbs) that react with platelet membrane glycoproteins only 
when the implicated drug is present. Although more than 100 
drugs have been associated with causing DIIT, recent reviews of 
available data show that carbamazepine, eptifibatide, ibuprofen, 
quinidine, quinine, oxaliplatin, rifampin, sulfamethoxazole, 
trimethoprim, and vancomycin are probably the most frequently 
implicated. Patients with DIIT typically present with petechiae, 
bruising, and epistaxis caused by an acute, severe drop in platelet 
count (often to <20,000 platelets/µL). Diagnosis of DIIT is 
complicated by its similarity to other non–drug-induced immune 
thrombocytopenias, including autoimmune thrombocytopenia, 
posttransfusion purpura, and platelet transfusion refractoriness, 
and must be differentiated by temporal association of exposure 
to a candidate drug with an acute, severe drop in platelet 
count. Treatment consists of immediate withdrawal of the 
implicated drug. Criteria for strong evidence of DIIT include (1) 
exposure to candidate drug–preceded thrombocytopenia; (2) 
sustained normal platelet levels after discontinuing candidate 
drug; (3) candidate drug was only drug used before onset of 
thrombocytopenia or other drugs were continued or reintroduced 
after resolution of thrombocytopenia, and other causes for 
thrombocytopenia were excluded; and (4) reexposure to the 
candidate drug resulted in recurrent thrombocytopenia. Flow 
cytometry testing for DDAbs can be useful in confirmation of 
a clinical diagnosis, and monoclonal antibody enzyme-linked 
immunosorbent assay testing can be used to determine the 
platelet glycoprotein target(s), usually GPIIb/IIIa or GPIb/IX/V, 
but testing is not widely available. Several pathogenic mechanisms 
for DIIT have been proposed, including hapten, autoantibody, 
neoepitope, drug-specific, and quinine-type drug mechanisms. A 
recent proposal suggests weakly reactive platelet autoantibodies 
that develop greatly increased affinity for platelet glycoprotein 
epitopes through bridging interactions facilitated by the drug is a 
possible mechanism for the formation and reactivity of quinine-
type drug antibodies. Immunohematology 2014;30:55–65.
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Drug-induced immune thrombocytopenia (DIIT) is an 
unusual disorder that occurs after exposure to prescription 
medications, herbal remedies, foods, and nutritional 
supplements, in which affected individuals produce drug-
dependent antibodies (DDAbs) that bind and bring about 
destruction of their platelets.1,2 Drug-induced bone marrow 
suppression can cause thrombocytopenia through decreased 
platelet production, and platelet destruction by drug-induced 
autoantibodies is a form of DIIT. However, in these forms of 
drug-induced thrombocytopenia, DDAbs are not typically 
involved. Heparin-induced thrombocytopenia (HIT) is 
another DIIT that occurs in 1 to 5 percent of patients receiving 
heparin. Patients affected by HIT develop antibodies against 
complexes of heparin and platelet factor 4 (PF4) that stimulate 
platelet activation through platelet Fc receptor engagement, 
resulting in clinically significant thrombosis. The pathogenesis 
of HIT is different from that of DIIT caused by nonheparin 
drugs, and the thrombocytopenia in HIT usually does not 
reach levels that result in bleeding symptoms; consequently, 
HIT will not be further discussed, but readers are referred to 
numerous excellent, recent, in-depth reviews on the subject.3–5 
The focus of this review will be on DIIT, in which patients 
develop drug-dependent platelet antibodies targeting platelet 
membrane glycoproteins (GPs) that cause clinically significant 
thrombocytopenia primarily by clearance of antibody-coated 
platelets in the reticulo-endothelial system (RES).
Incidence and Drugs Most Frequently Implicated
The exact frequency of DIIT is not known, but the overall 
incidence is estimated to be 10 cases per million population 
per year.6 Higher incidence is reported in specific patient 
populations, including 25 percent of critically ill patients,7 
the elderly,8 and patients taking the drugs quinine and 
sulfamethoxazole-trimethoprim who were reported to be at 
higher risk of developing DIIT—38 and 26 cases per million 
exposed, respectively.9 Thrombocytopenia associated with the 
GPIIb/IIIa inhibitors, abciximab, eptifibatide, and tirofiban 
occurs in approximately 1 to 2 percent of patients exposed to 
these drugs and as many as 10 percent of patients exposed to 
abciximab for the second time.10
Recently, several groups have mined data from available 
sources to determine those drugs most frequently associated 
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with DIIT.8,11–14 Reese et al.11 used published case reports, 
reference laboratory testing of patients’ sera for DDAbs over a 
13-year period, and data mining of 41 years’ worth of the U.S. 
Food and Drug Administration’s Adverse Event Reporting 
System (AERS) to identify those drugs most frequently 
implicated in causing DIIT. They identified 1468 drugs 
suspected of causing thrombocytopenia, and 102 of these 
were evaluated by all three methods. Only 23 of the 102 drugs 
demonstrated a causal association with thrombocytopenia by 
all three methods (Table 1). In a separate analysis focused on 
children (<18 years old) of the same published case reports 
and DDAb test data over a 5-year period (2008–2012), 34 
drugs showed a causal association with thrombocytopenia 
(Table 1).12 Garbe et al.14 used active surveillance of patients 
in 50 German hospitals (Berlin Case-Control Surveillance 
Study) to identify drugs that might cause DIIT. They 
identified 90 cases of acute immune thrombocytopenia, in 
which a drug was possibly associated. A total of 85 different 
drugs were involved, and 31 drugs were determined to be 
definitely (n = 7) or probably (n = 24) related to the patients’ 
thrombocytopenia. Tirofiban, abciximab, sulfamethoxazole-
trimethoprim, and flu vaccine were the most frequently 
implicated drugs. Arnold et al.13 analyzed data from the same 
case reports database used by Reese et al.,11 combined with 
a search of MEDLINE and EMBASE, of more than 72 years 
of DIIT case reports for only those who had been tested for 
DDAb by two or more laboratories. Using these criteria and 
four independent assessors, only 16 drugs met the criteria for 
a definite association with DIIT (Table 1).
Analysis of the most current data (2012) from our 
reference laboratory (Platelet and Neutrophil Immunology 
Lab, BloodCenter of Wisconsin, Milwaukee, WI) of all serum 
tests for DDAbs from patients with suspected DIIT showed 
that 101 different drugs were tested during this period (Table 
2). Vancomycin (n = 127), piperacillin-tazobactam (n = 34), 
sulfamethoxazole-trimethoprim (n = 43), cefepime (n = 24), 
and ceftriaxone (n = 15) were the five most frequently tested 
drugs, and there were 18 drugs for which DDAbs against 
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Table 1. Drugs frequently associated with drug-induced immune thrombocytopenia from literature sources









































































































* Heparin was excluded from the other reports because its pathogenic mechanism differs significantly from nonheparin drugs.
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platelets were detected using a flow cytometry assay (Table 
2). Carbamazepine, eptifibatide, ibuprofen, quinidine, quinine, 
oxaliplatin, rifampin, sulfamethoxazole, trimethoprim, and 
vancomycin are all represented in data from both Tables 1 
and 2, suggesting that these 10 drugs are the most frequently 
associated with DIIT caused by DDAbs. Although the drugs 
listed in Tables 1 and 2 are the most frequently reported, it 
should be pointed out that there are numerous other drugs1 
and even herbal remedies,15–17 foods,17–20 and beverages17,21,22 
that have been implicated in DIIT. Illicit drug use has also been 
associated with DIIT. Cocaine and heroin are sometimes cut 
or mixed with drugs known to cause DIIT, like quinine23,24 or 
levamisole.25 Testing for DDAbs can be helpful in making a di-
agnosis in this setting and should include testing with quinine 
to determine whether it has been added as an adulterant.
The rates of thrombocytopenia observed with chemo-
therapeutic agents are quite high, ranging from 21 to 70 
percent.26,27 Bone marrow suppression is the major cause 
of thrombocytopenia associated with this class of drugs.28 
However, DIIT has been reported in a number of cases involving 
various chemotherapeutic compounds.29–32 Oxaliplatin, a 
widely used platinum compound for the treatment of colorectal 
cancer, has been implicated in an increasing number of DIIT 
cases.26,29,32–34
The incidence data just described are useful in identifying 
drugs that are the top candidates for consideration in 
a thrombocytopenic patient with compatible temporal 
association and could be useful in hastening diagnosis and 
treatment. Clearly, good medical practice requires that the 
clinical criteria established for DIIT, together with laboratory 
confirmation, be applied to all patients suspected of DIIT, 
including exclusion or inclusion of all drugs to which the patient 
has been recently exposed. Another issue worth mentioning 
about the identification of drugs causing DIIT is that to 
have good available data, physicians, pharmacists, testing 
laboratories, and investigators must regularly report identified 
cases of DIIT. Unfortunately, when an accurate diagnosis is 
made, the case is often not reported to national databases (e.g., 
AERS) or is not published in the medical literature. It is my 
opinion that this is partly the result of the increasing difficultly 
clinicians and investigators face trying to publish a single 
clinical case report of a novel finding such as DIIT because of 
the reluctance of scientific journal editors. This trend continues 
at the risk that investigators will no longer bother to submit 
such cases, and this important information will be lost.
Clinical Features, Diagnosis, and Treatment
Patients with DIIT typically present with petechiae, 
bruising, and epistaxis caused by an acute, often-severe 
drop in platelet count. When thrombocytopenia is severe 
(i.e., ≤20,000 platelets/µL), mucosal bleeding can occur 
Drug-induced immune thrombocytopenia 
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* Drugs (n = 101) for which sera from patients with suspicion of drug-induced immune thrombocytopenia were tested in flow cytometry assay by Platelet & 
Neutrophil Immunology Lab, BloodCenter of Wisconsin, Milwaukee.
†Five most frequently tested drugs (number of patient samples tested).
‡Drugs (n = 18) for which drug-dependent antibodies (DDAbs) were detected (number of DDAbs detected).
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in the gastrointestinal or genitourinary tracts (so-called 
wet purpura). In extreme cases, intracranial or pulmonary 
hemorrhage resulting in fatalities has been reported. Platelet 
counts usually fall rapidly from normal or near-normal 
levels to nadirs in the single digits within several hours of 
a repeat drug exposure. For patients receiving a drug for 
the first time, 5 to 7 days of exposure is usually required for 
sensitization. Patients previously sensitized can experience 
rapid drops in platelet counts within 1 to 2 hours of repeat 
exposure. DIIT is a diagnosis of exclusion, i.e., the exclusion 
of the many other causes of thrombocytopenia. Therefore, the 
diagnosis is complex and is often mistaken for other immune 
platelet disorders such as immune thrombocytopenia (ITP),35 
posttransfusion purpura (PTP),36 or platelet transfusion 
refractoriness (PTR),37 especially for patients receiving 
multiple medications.
ITP usually presents as isolated thrombocytopenia most 
commonly occurring in response to an unknown stimulus 
and is caused by nondrug autoantibodies that bind and 
destroy autologous platelets. ITP can also develop secondarily 
to other autoimmune disorders, viral infections, and certain 
drugs (e.g., procainamide and gold salts)6; however, in this 
form of DIIT, true autoantibodies develop, and also do not 
require the presence of drug for their detection in laboratory 
tests. Distinguishing DIIT from ITP can be quite challenging; 
however, it is important to do so to prevent patients with DIIT 
from undergoing unnecessary, invasive treatments.38
PTP is a rare disorder, occurring approximately 5 to 10 
days after a blood transfusion, in which there is an acute, 
severe drop in platelet count very similar in timing and 
severity of the thrombocytopenia that occurs in DIIT. PTP 
is distinguishable from DIIT by its association with a blood 
transfusion rather than medication, but this distinction can be 
more difficult when a patient receives both. Another difference 
is that platelet-specific antibodies, most often targeting human 
platelet alloantigen (HPA)-1a, are often detected in the sera of 
patients with PTP, whereas DDAbs specific for the suspected 
drug, and not HPA antibodies, are detected in DIIT.
PTR develops most often in oncology patients, and occurs 
when posttransfusion platelet increments do not achieve 
expected levels despite multiple platelet transfusions. Although 
the majority of PTR is attributable to nonimmune causes (e.g., 
bone marrow suppression, fever, sepsis, etc.), immune forms 
caused by class I HLA antibodies and, rarely, platelet-specific 
antibodies also occur. Distinguishing thrombocytopenia 
caused by DIIT from that caused by PTR can be particularly 
challenging. A major complicating factor is that many patients 
at risk of developing PTR also receive drugs reported to 
have caused DIIT, so a detailed review of platelet counts and 
timing of drug exposures is critical in this setting. Testing 
of a patient’s serum for HLA and platelet-specific antibodies 
can be helpful in identifying possible immune causes of PTR. 
However, discontinuing candidate drugs, when possible, with 
careful observation for a rise in platelet count over the course 
of 3 to 4 days may be required in exceptionally difficult cases.
Clinical criteria that have been established to implicate a 
suspected drug include the following39:
1. Exposure to the candidate drug preceded thrombo-
cytopenia.
2. Recovery from thrombocytopenia was complete and 
sustained after discontinuing candidate drug.
3. Candidate drug was the only drug used before the 
onset of thrombocytopenia, or other drugs were 
continued or reintroduced after discontinuation of 
the candidate drug with a sustained normal platelet 
count.
4. Other causes for thrombocytopenia were excluded.
5. Reexposure to the candidate drug resulted in recurrent 
thrombocytopenia.
Evidence is considered Definite if criteria 1, 2, 3, and 4 are 
met; Probable if criteria 1, 2, and 3 are met; Possible if criterion 
1 only is met; and Unlikely if criterion 1 is not met.
For patients receiving chemotherapy who exhibit 
thrombocytopenia, it is common to attribute this complication 
to suppression of megakaryocytopoiesis, a recognized side 
effect of these classes of drugs. However, as mentioned 
previously, DIIT has been reported to develop from exposure 
to these drugs. Accordingly, it is important to consider DIIT 
in patients undergoing chemotherapy who have a sudden, 
isolated drop in platelet levels.
Once a clinical diagnosis of DIIT is established, treatment 
consists of immediate withdrawal of the implicated drug, and 
platelet counts should be monitored until they reach normal, 
sustained levels. Patients with severe thrombocytopenia or 
hemorrhage may require platelet transfusions.40 Treatment 
with corticosteroids has not been shown to be an effective 
treatment in DIIT.6,41 Platelet levels typically begin to recover 
in 3 to 4 days, as the drug is cleared from the circulation, 
and attain normal levels by 5 to 7 days after stoppage of the 
offending drug.1 It is possible for drug clearance and resolution 
of thrombocytopenia to be prolonged in patients with renal 
impairment.6 
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Laboratory Testing for Drug-Dependent Platelet 
Antibodies
Detection of serum antibodies that react with normal 
platelets only in the presence of the suspected drug is helpful 
in confirming a clinical diagnosis of DIIT. Several different 
methods have been used during the years for detection of 
DDAbs,6,13,42 but use of flow cytometry with intact platelets is 
one of the most sensitive assays currently in use.29,42–44 A typical 
assay involves incubation of serum with  group O platelets and 
buffer or drug in the well of a microtiter plate, followed by 
washing of the platelets to remove unbound immunoglobulins. 
The test well incubated with buffer is washed in buffer, and 
the well with drug is washed with buffer containing drug, 
usually at the therapeutic concentration. Platelets are then 
incubated with a combination of fluorescent-labeled anti-
immunoglobulin reagents: fluorescein-isothiocyanate–labeled 
anti-human immunoglobulin (Ig) G and phycoerythrin-
labeled anti-human IgM. Fluorescent events are acquired on 
a flow cytometer with simple forward scatter and side-scatter 
gates set to identify platelets. Stronger median fluorescence 
intensity values obtained with samples in the presence of drug 
compared with those without drug are considered positive 
for DDAbs (Fig. 1). Sera from normal, healthy individuals 
previously tested and shown not to have DDAbs and sera from 
patients previously shown to have drug-dependent antibodies 
should be tested in each assay as important negative and 
positive controls, respectively. Although this testing is available 
in the United States,45 unfortunately, it is not more widely 
available because it requires an experienced laboratory with 
access to sufficient rare control samples and a large inventory 
of various pharmaceuticals. There has been a recent call to 
create broader access to laboratory testing.13
Several issues encountered with flow cytometry testing for 
DDAbs include insolubility of some drugs, non-DDAbs present 
in patient sera, and the fact that some DDAbs recognize only 
drug metabolites. Because most drugs have affinity for albumin 
in circulation, drugs that are poorly soluble in buffer can often 
be adequately solubilized in a buffer containing 5 percent 
bovine serum albumin.42 Non-DDAbs, e.g., autoantibodies 
and class I HLA antibodies, are easily identified because they 
bind to platelets in both the presence and absence of drug, 
and strong non-DDAbs can mask the presence of a DDAb 
in testing. Absorption of sera with platelets in the absence of 
drug before testing will remove non-DDAbs and reveal DDAbs 
present. DDAbs are encountered that show reactivity only with 
metabolites of the native drug.46,47 In these cases, metabolites 
can sometimes be obtained from pharmaceutical companies or 
other commercial sources, and as a last resort, urine collected 
from someone having taken the drug for several days can be 
Fig. 1 Fluorescence histograms from immunofluorescence detection of IgG drug-dependent platelet antibodies by flow cytometry assay. 
Normal isolated platelets were incubated with sera and washed, and platelet-bound antibodies were detected with fluorescent anti-human 
IgG. (A) Normal serum incubated with platelets in the presence of either sulfamethoxazole (black histograms) or buffer (white histograms) 
shows low IgG fluorescence, indicating no antibodies are present. (B) Serum from a patient with suspected drug-induced thrombocytopenia 
after exposure to sulfamethoxazole-trimethoprim incubated with platelets showing high IgG fluorescence (MFI = 453.2) only with 
sulfamethoxazole, indicating the presence of sulfamethoxazole drug-dependent antibodies. Median fluorescence intensity (MFI) values are 
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used as a source of metabolites for testing after adjusting the 
pH and salt concentration.
Enzyme-linked immunosorbent assays (ELISAs) like the 
modified antigen-capture ELISA (MACE)43 and immuno-
blotting procedures48–50 are primarily used to identify the 
platelet GPs that DDAbs target. In the MACE, platelet 
sensitization with patient’s serum and drug is the same as 
that just described for flow cytometry. Sensitized platelets 
are then lysed in detergent, the platelet GP–drug–antibody 
complexes are captured in a microtiter plate well with specific 
monoclonal antibodies, and DDAbs are detected with enzyme-
labeled anti-human IgG reagents. The majority of DDAbs 
bind to GPIIb/IIIa,29,42,43,51 the major fibrinogen receptor, or 
GPIb/IX/V,52,53 a receptor for von Willebrand factor on 
platelets. There has been a single report of a carbimazole-
dependent platelet antibody targeting platelet endothelial cell 
adhesion molecule-1 (PECAM-1/CD31).54 Flow cytometry 
assays using platelets from patients with the platelet function 
disorders Glanzmann thrombasthenia (platelets lack GPIIb/
IIIa) and Bernard-Soulier syndrome (platelets lack GPIb/IXV) 
have also been used successfully to identify the platelet GP 
targets of DDAbs.29,55
An in vivo mouse model was recently developed in 
which normal human platelets and human serum containing 
strong quinine-dependent platelet antibodies are transfused 
into nonobese diabetic/severe combined immunodeficient 
(NOD/scid) mice and allowed to circulate. Rapid clearance of 
platelets occurred after intraperitoneal injection of quinine.56 
This model might be useful in detecting low-affinity DDAbs 
that wash off platelets and go undetected in conventional 
laboratory tests or those induced by drug metabolites, which 
the authors showed could be produced by the mice after 
intraperitoneal injection of the native drug.56
The clinical sensitivity and specificity of the different assays 
is unknown because it is extremely difficult to obtain the large 
numbers of samples that would be required both from patients 
with a clinical diagnosis of DIIT and from patients taking the 
drugs who did not exhibit thrombocytopenia. In a single study 
of 59 patients exposed to vancomycin, 29 of 31 who met the 
criteria for vancomycin-induced thrombocytopenia tested 
positive for vancomyin-dependent platelet antibodies by flow 
cytometry, and all 25 who did not develop thrombocytopenia 
gave negative results. In addition, 10 samples from patients not 
exposed to vancomycin but with quinine-dependent antibodies 
tested negative for vancomycin DDAbs, and only 1 of 451 sera 
from normal healthy subjects never exposed to vancomyin 
had weak IgM-positive reactivity.51 Altogether, these results 
indicate that the flow cytometry assay had high sensitivity 
(93.5%) and specificity (99.8%) for detection of DDAbs. It has 
been suggested that tests for DDAbs are not practical for use in 
clinical decision making because the testing is available in only 
a handful of laboratories in the world, DDAbs are not always 
detected, and there are claims of suboptimal test turnaround 
times. However, it certainly can be argued that for cases with 
a difficult diagnosis that knowing the results of DDAb testing, 
even within 2 to 3 days, is probably more clinically useful than 
continuing to expose a patient with undiagnosed DIIT to the 
offending drug.
Pathogenic Mechanisms
DDAbs that are the cause of DIIT are exquisitely unique in 
their ability to bind to specific platelet membrane GPs only in 
the presence of the drug that induced them. In fact, the drug 
is so critical to the reactivity of these antibodies that, during 
the performance of DDAb assays, they will easily and rapidly 
wash off the platelets if drug is not present throughout testing. 
Several mechanisms have been proposed to explain the 
formation of these most interesting antibodies (Fig. 2).6,57–60
Hapten Mechanism
Haptens are low-molecular-weight (usually <5000 
daltons) molecules that are not capable of eliciting an immune 
response unless they are coupled to a larger carrier protein. 
Drugs such as penicillin and some cephalosporin drugs when 
covalently linked to cell surface proteins can elicit drug-
specific antibodies. This mechanism is well described for 
DDAbs targeting red blood cells that cause immune hemolytic 
anemia.61 Although it is a potential mechanism to explain 
DIIT, attempts in our laboratory to detect DDAbs with drug-
coated platelets have not been successful to date, and there are 
no known reports in which hapten-induced antibodies have 
been detected in DIIT.1,59
Autoantibody Mechanism
There are reports of patients who exhibited acute, 
severe thrombocytopenia after exposure to specific drugs, 
but no DDAbs can be detected in their serum. However, 
autoantibodies that are not dependent on drug can be detected 
in these patients’ sera, suggesting that the drug induced a true 
autoantibody, but this is very difficult to prove.62
Neoepitope Mechanism
The most popular mechanism espoused for DDAb 
formation is the neoepitope mechanism (Fig. 2). It is well 
established that most drugs in circulation make low-affinity 
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Fig. 2 Proposed mechanisms for drug-induced antibody formation and platelet destruction. (1) Hapten-dependent antibody: Covalent 
binding of drug/hapten to platelet membrane protein(s) induces antibody specific to drug/hapten. (2) Autoantibody: Drug induces formation 
of a true platelet autoantibody. (3) Fiban-type drug-dependent antibody: Drug binding to GPIIb/IIIa induces neoepitopes that are recognized 
by drug-dependent antibody. (4) Drug-specific antibody: Antibody recognizes mouse components of mouse/human chimeric Fab fragments 
of drug bound to platelet GPIIb/IIIa. (5) Quinine-type drug-dependent antibody: Drug and platelet glycoprotein together form a combinatorial 
epitope recognized by drug-dependent antibody. (6) Quinine-type drug-dependent antibody: Drug induces antibody that binds more tightly 
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interactions with many different proteins in the plasma, 
especially albumin, but also probably platelet GPs, e.g., 
GPIIb/IIIa. These interactions are speculated to induce 
conformational changes in the protein structures that elicit 
DDAbs in certain individuals. However, when drug is cleared 
from the circulation and the conformation of the platelet 
protein reverts to its native state, DDAbs, although still present, 
can no longer bind and destroy the platelets (Fig. 2). It is 
proposed that the platelet GPIIb/IIIa inhibitors, tirofiban and 
eptifibatide, small-molecule fibrinogen receptor antagonists 
(fibans), induce DDAbs by this mechanism.6,63 Fibans are a 
widely used class of drugs capable of preventing restenosis 
in patients undergoing percutaneous transluminal coronary 
angioplasty (PTCA) procedures. Interestingly, an unusual 
aspect of fiban-dependent antibodies is that they can occur 
naturally in approximately 2 percent of normal people.63,64
Drug-Specific Mechanism
Abciximab (Reopro) is a chimeric (mouse-human) 
monoclonal antibody Fab fragment specific for GPIIIa used 
primarily in PTCA procedures to prevent thrombus formation. 
Like the previously mentioned fibans, it blocks interactions 
of fibrinogen with GPIIb/IIIa to prevent platelet aggregation. 
Approximately 1 to 2 percent of patients receiving abciximab 
exhibit acute thrombocytopenia within a few hours of receiving 
the drug.10 Although abciximab binds tightly to platelets, it does 
not cause thrombocytopenia by macrophage clearance in the 
RES because it lacks the immunoglobulin Fc; rather, affected 
patients make drug-specific antibodies that appear to recognize 
murine sequences in the complimentary determining region 
3 (CDR3) region of abciximab (Fig. 2).65,66 Like DIIT induced 
by fibans, some patients affected with abcixmab-induced 
immune thrombocytopenia also have preexisting antibodies in 
their serum.66 Many normal, healthy people never exposed to 
abciximab also have IgG antibodies that react with abciximab-
coated platelets65,67; however, these antibodies recognize the 
cleaved end of the Fab fragment that is created when the drug 
is treated with papain. It is unknown whether Fab-reactive 
antibodies seen in healthy people can cause DIIT should these 
individuals ever be exposed to the drug.
Quinine-Type Drug Mechanism
The classic DDAbs induced by drugs such as quinine, 
quinidine, sulfamethoxazole, and vancomycin attach tightly 
to platelets only in the presence of the sensitizing drug, and 
most often target GPIIb/IIIa or GPIb/IX/V. These antibodies 
bind their epitopes by their Fab domains,68 indicating that 
their reactivity with platelets is not the result of drug–
antibody immune complexes engaging platelet Fc receptors, 
as is the case with heparin-PF4 antibodies that cause HIT. 
Early mechanisms proposed to explain platelet destruction by 
quinine-type DDAbs were (1) the previously described hapten 
mechanism; however, quinine-type antibodies still react with 
platelets in the presence of large concentrations of soluble drug 
that should block their binding if they were produced by this 
mechanism; (2) drug-induced conformational changes in the 
GPs that are targeted by DDAbs; and (3) compound epitopes 
consisting of both drug and platelet protein form that are 
recognized by antibodies. However, none of these proposed 
mechanisms have been proven.
The mechanisms by which quinine-type DDAbs form 
and react with platelets have been intensely studied in the 
laboratory of Dr. Richard Aster at the BloodCenter of Wisconsin 
in Milwaukee. Using chimeric human/rat GPIIIa and targeted 
mutants of human GPIIIa, they identified a 17–amino acid (aa 
50–66) stretch spanning the hybrid and plexin-semaphorin-
integrin (PSI) domains of GPIIIa that was recognized by all 
three antibodies only in the presence of quinine.50 Substitution 
in human GPIIIa of only three amino acids (Ala50, Arg62, or 
Asp66) abolished DDAb reactivity, as did reduction of wild-
type GPIIIa with 2-mercaptoethanol, indicating that disulfide 
linkages are also important in formation of this epitope. 
Burgess et al.52 previously identified a peptide sequence 
(aa 282–293) in GPIbα that was also required for reactivity 
of a single quinine DDAb, and studies by Asvadi et al.69 
demonstrated that amino acid residues Arg110 and Gln115 in 
GPIX were critical for binding of six quinine DDAbs.
Later studies again by the Aster group49 showed that 14 
quinine DDAbs, including the three originally studied, all 
recognized a small 29-kD recombinant fragment of GPIIIa 
that included the three amino acids (Ala50, Arg62, or Asp66) 
previously shown to be critical for DDAb binding. Additional 
studies with blocking monoclonal antibodies and overlapping 
mutant GPIIIa constructs showed that as many as eight 
different overlapping epitopes were recognized by the 14 
different quinine DDAbs, leading this group to propose that 
DDAbs induced by quinine, and presumably other drugs, 
do not recognize a single distinct epitope on a GP. This 
result further indicates that mechanisms proposing DDAbs 
recognize drug-induced conformational changes elsewhere in 
platelet membrane GPs are not viable explanations for DDAb 
formation.49
In other studies, the Aster lab59 found both the classic 
drug-dependent platelet-reactive antibodies and drug-specific 
antibodies in plasma from 6 of 7 patients who exhibited DIIT 
after exposure to quinine. DDAbs reacted with GPIIb/IIIa 
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or GPIb/IX/V on platelets only in the presence of quinine. 
Drug-specific antibodies bound directly to quinine that was 
covalently linked to human serum albumin, and this reactivity 
was inhibited by excess soluble quinine. Despite recognizing 
different targets, both types of antibodies were identical in 
their drug specificity, and this suggests that both are produced 
against a similar antigen as part of the same B-cell immune 
response. Based on these findings, the authors proposed a 
novel model in which patients have autoantibodies with only 
weak reactivity for platelet GP epitopes in the absence of drug, 
but that this reactivity is significantly enhanced through 
bridging interactions by drug binding between both the 
protein and antibody; the resultant sandwich entraps a drug at 
the antigen–antibody interface and greatly increases antibody 
binding energy for the GP autoepitope (Fig. 2).6,59 Two quinine-
dependent mouse monoclonal antibodies recently developed 
by Aster’s group with specificity for epitopes on human GPIIb 
will be valuable tools to help further elucidate the complex 
mechanisms responsible for DIIT.70
Summary
DIIT is a relatively uncommon, but often-undiagnosed, 
disorder that can occur after exposure to numerous drugs. 
Several recent large analyses of data from multiple sources 
indicate that the drugs carbamazepine, eptifibatide, ibuprofen, 
quinidine, quinine, oxaliplatin, rifampin, sulfamethoxazole, 
trimethoprim, and vancomycin are most often implicated. 
Diagnosis is complex and involves excluding other causes of 
thrombocytopenia and ascertainment of the patient’s complete 
medication history. Laboratory testing of patient’s serum for 
DDAbs can be very useful in confirming a clinical diagnosis 
and, with broader access, will be used more often. The hallmark 
of treatment is immediate cessation of the offending drug(s) 
and platelet transfusions for patients with severe bleeding 
symptoms. DDAbs usually target GPIIb/IIIa and GPIb/IX/V 
on the platelet membrane surface. Several mechanisms have 
been proposed to explain the development and reactivity of 
DDAbs, and a recent hypothesis suggests that many are weakly 
reactive platelet autoantibodies that develop greatly increased 
affinity for platelet GP epitopes through bridging interactions 
facilitated by the drug. Data obtained from studies using newly 
developed drug-dependent monoclonal antibodies and mouse 
models of DIIT should yield important new knowledge about 
this fascinating disorder.
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